A new prostate cancer therapy in clinical trials could treat patients resistant to treatment through targeting the disease on a molecular level, based on Cleveland Clinic research.
Neoadjuvant and Adjuvant Combination Therapy in Locally Advanced Renal Cell Carcinoma Raises Toxicity Concerns
A new study finds neoadjuvant and adjuvant monotherapy using the checkpoint inhibitor durvalumab is well-tolerated by patients with locally advanced renal cell carcinoma, but adding a second checkpoint inhibitor, tremelimumab, caused complications that forced some patients to discontinue the combination therapy.
Sunitinib Treatment Breaks Feasible for Metastatic Renal Cell Carcinoma
Intermittent sunitinib dosing does not compromise clinical efficacy and is feasible in patients with previously untreated metastatic renal cell carcinoma, according to a phase 2 Cleveland Clinic study.